|

Determining the Mechanisms of Loss of CAR T Cell Persistence

RECRUITINGSponsored by University College, London
Actively Recruiting
SponsorUniversity College, London
Started2023-10-18
Est. completion2025-12-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05809284

Summary

A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
2. Written informed consent

Exclusion Criteria:

1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol

Conditions6

Acute Lymphoblastic Leukemia Not Having Achieved RemissionAcute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in RelapseCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.